Seres Therapeutics, Inc.MCRBNASDAQ
LOADING
|||
Switch Symbol:
Gross Profit Growth Under Pressure
Trending lower, below historical average, modest growth trend.
Left:
||||
Year-over-year gross profit growth rate
Latest
-1127.67%
↓ 700% below average
Average (39q)
-140.96%
Historical baseline
Range
High:382.96%
Low:-2706.96%
CAGR
+8.9%
Consistent expansion
| Period | Value |
|---|---|
| Q3 2025 | -1127.67% |
| Q2 2025 | 69.97% |
| Q1 2025 | 0.00% |
| Q4 2024 | 0.00% |
| Q3 2024 | 0.00% |
| Q2 2024 | 0.00% |
| Q1 2024 | -100.00% |
| Q4 2023 | 0.00% |
| Q3 2023 | -100.00% |
| Q2 2023 | 279.09% |
| Q1 2023 | 1.67% |
| Q4 2022 | -1413.73% |
| Q3 2022 | 108.06% |
| Q2 2022 | -11.96% |
| Q1 2022 | -29.21% |
| Q4 2021 | -134.01% |
| Q3 2021 | 382.96% |
| Q2 2021 | -30.13% |
| Q1 2021 | -222.95% |
| Q4 2020 | -615.38% |
| Q3 2020 | -76.56% |
| Q2 2020 | -26.18% |
| Q1 2020 | 161.07% |
| Q4 2019 | -18.82% |
| Q3 2019 | -110.01% |
| Q2 2019 | 65.48% |
| Q1 2019 | -10.10% |
| Q4 2018 | 3.30% |
| Q3 2018 | 24.80% |
| Q2 2018 | 0.25% |
| Q1 2018 | 7.13% |
| Q4 2017 | -2706.96% |
| Q3 2017 | 104.02% |
| Q2 2017 | -17.04% |
| Q1 2017 | 0.53% |
| Q4 2016 | -54.74% |
| Q3 2016 | 41.95% |
| Q2 2016 | -50.87% |
| Q1 2016 | 8.59% |
| Q4 2015 | -41.12% |